Show simple item record

dc.contributor.authorGerosa, Maria
dc.contributor.authorSchioppo, Tommaso
dc.contributor.authorArgolini, Lorenza Maria
dc.contributor.authorSciascia, Savino
dc.contributor.authorRamirez, Giuseppe Alvise
dc.contributor.authorMoroni, Gabriella
dc.contributor.authorSinico, Renato Alberto
dc.contributor.authorBonelli, Grazia
dc.contributor.authorAlberici, Federico
dc.contributor.authorMescia, Federica
dc.contributor.authorMoroni, Luca
dc.contributor.authorTamborini, Francesco
dc.contributor.authorMiraglia, Paolo
dc.contributor.authorBellocchi, Chiara
dc.contributor.authorBeretta, Lorenzo
dc.contributor.authorRoccatello, Dario
dc.contributor.authorDagna, Lorenzo
dc.contributor.authorBozzolo, Enrica
dc.contributor.authorCaporali, Roberto
dc.date.accessioned2022-07-08T23:30:26Z
dc.date.available2022-07-08T23:30:26Z
dc.date.issued2022-04-22
dc.identifier.issn2076-393X
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/338953
dc.description.abstractVulnerable subjects, including systemic lupus erythematosus (SLE) patients, have been prioritised to receive anti-SARS-CoV-2 vaccines. Few data about the safety of these vaccines in SLE are available. The aim of our study is to investigate the safety of anti-SARS-CoV-2 vaccines in SLE. We included 452 SLE patients, referring to seven tertiary centres, who were immunised. A total of 119 (26%) reported side effects (SE) after the first and/or the second shot (the most frequent SE were fever, local reaction, fatigue, and arthralgia). Patients with constitutional symptoms and those on an immunosuppressive regimen (especially belimumab) showed more SE. In addition, 19 (4%) had a flare after the immunisation (flares classified by organ involvement: six musculoskeletal with constitutional symptoms, four renal, three cardio-respiratory, three haematological, two mucocutaneous). None of the patients needed hospitalisation and none died. Moreover, 15 required a transient increase in corticosteroids and four were treated with steroid pulses. One patient required an additional rituximab course. Anti-dsDNA, moderate/high DAS before vaccine, and belimumab were found more frequently in patients with disease flare. Anti-SARS-CoV-2 vaccines are safe in SLE patients, and they should be recommended in these patients, as the potential benefits widely outweigh the risk of SE. Treatment adjustment might be considered with the aim of minimising SE risk and flare.
dc.format.mediumElectronic
dc.publisherMDPI AG
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectSARS-CoV-2 infection
dc.subjectSARS-CoV-2 vaccine
dc.subjectflare
dc.subjectimmunisation
dc.subjectside effect
dc.subjectsystemic lupus erythematous
dc.titleThe Impact of Anti-SARS-CoV-2 Vaccine in Patients with Systemic Lupus Erythematosus: A Multicentre Cohort Study.
dc.typeArticle
dc.publisher.departmentFaculty of Clinical Medicine
dc.date.updated2022-07-07T09:38:49Z
prism.issueIdentifier5
prism.numberARTN 663
prism.publicationDate2022
prism.publicationNameVaccines (Basel)
prism.startingPage663
prism.volume10
dc.identifier.doi10.17863/CAM.86360
dcterms.dateAccepted2022-04-20
rioxxterms.versionofrecord10.3390/vaccines10050663
rioxxterms.versionVoR
dc.contributor.orcidSchioppo, Tommaso [0000-0001-8359-5131]
dc.contributor.orcidSciascia, Savino [0000-0003-1266-9441]
dc.contributor.orcidRamirez, Giuseppe Alvise [0000-0002-2889-366X]
dc.contributor.orcidSinico, Renato Alberto [0000-0002-9470-218X]
dc.contributor.orcidMescia, Federica [0000-0002-2759-4027]
dc.contributor.orcidTamborini, Francesco [0000-0001-8574-3548]
dc.contributor.orcidBellocchi, Chiara [0000-0001-8326-7904]
dc.contributor.orcidBeretta, Lorenzo [0000-0002-6529-6258]
dc.contributor.orcidRoccatello, Dario [0000-0002-4419-6813]
dc.identifier.eissn2076-393X
rioxxterms.typeJournal Article/Review
cam.issuedOnline2022-04-22
cam.depositDate2022-07-07
pubs.licence-identifierapollo-deposit-licence-2-1
pubs.licence-display-nameApollo Repository Deposit Licence Agreement


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International